IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Afr…
$271.83+2.62%
报价 2026-11-06
市值
$44.8B
EV
$58.58B
PE (TTM)
33.1x
预期 PE (FY2026)
21.0x
52 周区间距高点 -2.7%
$156.66$279.36
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
does not hit growth, cheap, or GARP pool
爆发潜力
2026-11-07未命中✗ 收入线✗ EPS 线
| 财年 | 收入倍数 | EPS | PE |
|---|---|---|---|
| FY+22027-12 | 1.1x | 12.81 → 14.16（1.1x） | 19.2 |
| FY+32028-12 | 1.1x | 12.81 → 15.91（1.2x） | 17.1 |
毛利率 26% · TTM 收入 $17311M · 基数 EPS 12.81（调整后）
电话会信号
辅助标签Q3 20262026-10-27
需求加速AI 词频高积压订单词频高上调指引
指引 上调
信心 5
分析师 4
“Last 12-month net new bookings up 14% year over year, increasing for 5 consecutive quarters, supporting long-term growth.”
原文引用（2）
- 需求加速：our last 12-month net new bookings have now increased for 5 consecutive quarters.
- 上调指引：We are raising our full year 2026 guidance for revenue for adjusted EBITDA, and for adjusted diluted earnings per share.
蓝色标签在暴涨研究中略有区分度；悬停查看口径。
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| IQVIQVIA Holdings Inc. | $44.8B | +2.6% | +8.0% | 32.9% | 33.1x | 16.6x | 16.9x | |
| CAHCardinal Health, Inc. | $62.92B | +1.5% | +3.9% | 4.3% | 31.6x | 16.9x | 11.9x | |
| HUMHumana Inc. | $52.08B | +5.3% | +25.8% | 11.7% | 41.8x | 17.8x | 69.7x | |
| AAgilent Technologies, Inc. | $49.28B | +1.7% | +6.1% | 26% | 27.1x | 23.0x | 39.3x | |
| WATWaters Corporation | $44.93B | +1.0% | +103.6% | 58.9% | 28.0x | 18.3x | 83.3x | 高增长 |
| HLNHaleon plc | $40.19B | -0.1% | – | 61.8% | 21.8x | 14.3x | – | |
| GEHCGE HealthCare Technologies Inc. | $37.25B | -1.6% | +6.5% | 40.3% | 21.3x | 14.0x | 30.9x | |
| ALCAlcon Inc. | $36.23B | -2.1% | – | 54.8% | 37.0x | 21.0x | – | |
| MTDMettler-Toledo International Inc. | $34.51B | +2.6% | +6.0% | 57.5% | 29.1x | 22.2x | 40.6x | |
| 同行中位数 | – | – | +6.3% | 47.6% | 28.5x | 18.1x | 39.9x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
| Metric | 2026-06-30 Q2 2026 | 2026-03-31 Q1 2026 | 2025-12-31 Q4 2025 | 2025-09-30 Q3 2025 | 2025-06-30 Q2 2025 | 2025-03-31 Q1 2025 | 2024-12-31 Q4 2024 | 2024-09-30 Q3 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $4.37B | $4.15B | $4.36B | $4.1B | $4.02B | $3.83B | $3.96B | $3.9B |
| Gross Margin | 32.9% | 32.6% | 6.7% | 33.5% | 32.9% | 33.9% | 34.8% | 35.4% |
| Operating Margin | 11.6% | 12.4% | 16.8% | 13.5% | 12.6% | 13% | 15.8% | 14.1% |
| Net Income | $256M | $274M | $514M | $331M | $266M | $249M | $437M | $285M |
| Diluted EPS | 1.53 | 1.61 | 2.99 | 1.93 | 1.54 | 1.4 | 2.42 | 1.55 |
| Operating Cash Flow | $558M | $618M | $735M | $908M | $443M | $568M | $885M | $721M |